Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at deadly lung cancer

NCT ID NCT07509034

First seen Apr 11, 2026 · Last updated May 21, 2026 · Updated 9 times

Summary

This early-phase study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called B7-H3. The study includes up to 40 adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that did not respond to or returned after standard therapy. Participants will receive chemotherapy before the modified cells are infused, and will be monitored closely for safety and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.